LuinaBio is highly experienced in working with strict anaerobic cultures. We have produced biomass for probiotics systems using a variety of bacterial strains. We have manufactured recombinant proteins, whole cell vaccines, viral vaccines, purified plant extracts, probiotics and synthetic molecules for pre-clinical, phase I, II and III human clinical trials, and commercial veterinary products for clients within Australia and internationally in the United States, New Zealand and Asia.
Many complex protein macromolecules that require extensive post-translational modification for activity, such as human monoclonal antibodies, cannot currently be produced in E. coli and must be produced in phylogenically higher Eukaryotic organisms such as yeast, fungi, mammalian and plant cells.
LuinaBio can use Saccharomyces cerevisiae, a species of yeast, in fermentation to produce biopharmaceuticals. The advantages of using S. cerevisiae as a cell factory for the production of biopharmaceuticals is the wealth of information about the organism available through scientific databases, sequenced genomes and molecular modification. These provide an extensive knowledge base for continued engineering of the organism.
We have also extracted API’s from anaerobic cultures.
LuinaBio can offer our clients in regard to fermentation and related services that include:
- Anaerobic cell bank preparation and qualification
- Fermentation and subsequent downstream purification
- Upscale and downscale fermentation optimization
- Anaerobic fermentation from 5L up to 500L
- Anaerobic mid-stream and downstream processing
- Anaerobic lyophilisation of live cultures
- Anaerobic product packaging
Our manufacturing processes can be operated in numerous modes (e.g. batch, fed batch and perfusion) and LuinaBio is able to offer a full suite of manufacturing, both whole cell preparations, recombinant products from microbial hosts, and naturally produced cellular products. Processing can be carried out as either non-GMP or GMP.